GENE ONLINE|News &
Opinion
Blog

2020-05-29| Technology

What to Expect from the ASCO20 Virtual Program

by GeneOnline
Share To

Photo Courtesy: ASCO

Taking the COVID-19 pandemic into consideration, last March, the organizers of the American Society of Clinical Oncology (ASCO), decided to convert their highly regarded annual meeting into a virtual format. Originally scheduled to take place in Chicago for 5 days, the conference will now transpire as an online program between May 29 – 31. Here is a brief preview of what to expect from the event.

The ASCO annual meeting is more than just a scientific congregation of physicians, researchers, and industry professionals reporting on the latest advances in cancer research. It is also an opportunity for education and patient advocacy. While a virtual program may not be an ideal replacement for the in-person meeting to achieve its full potential, the decision is the right one, considering the circumstances. Besides, it offers access to a horde of participants around the globe, who might have otherwise skipped the event. We attempted to give a glimpse of what to look forward to at the conference.

 
Anticipated Clinical Trial Results

In their official website, ASCO announced some of the top studies to be presented at the meeting. They include:

Plenary Session
Other Sessions
 
Select Company Presentations
  1. The use of tumor mutational burden (TMB) as a pan-tumor genomic biomarker across a variety of cancers
  2. FMI and Flatiron Health’s clinico-genomic database demonstrating that the combination of TMB and PD-L1 can better predict immunotherapy response in lung cancer patients (TPS2087)

 

References
  1. https://meetings.asco.org/am/virtual-program

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
Kyverna’s Lupus Nephritis Cell Therapy Received FDA Clearance, Aiming for Phase 1 Trial in 2023
2022-11-16
Roche’s Gantenerumab Fails Trials In Alzheimer’s Disease
2022-11-15
LATEST
Axsome’s AXS-05 Achieves Endpoints In Alzheimer’s Agitation Trial
2022-11-29
Spectrum to Cut 75% of Staff and NSCLC Program Following CLR
2022-11-28
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
2022-11-28
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
2022-11-28
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
2022-11-28
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!